Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | TOP2A | P11388 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL3836 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL31517322 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL30712226 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL14577671 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL9971346 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3927536 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL5531617 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29726458 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10278 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL418714 | 0.99 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558308-B2 | Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents | C.R. BARD, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260034236-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2026-02-05 | — | — | US | claimed |
| EP-4570272-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | claimed |
| EP-4570834-A1 | AFFIBODY MICELLE DRUG CONJUGATE | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | claimed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | claimed |
| CN-119950727-A | Pharmaceutical combination for the treatment of cancer | 能力制药公司 | 2025-05-09 | — | — | CN | claimed |
| WO-2025047983-A1 | NOVEL PRODRUG-TYPE ANTICANCER AGENT TARGETING CANCER-SPECIFIC ENZYME ACTIVITY | 国立大学法人 東京大学 | 2025-03-06 | — | — | WO | claimed |
| WO-2025046537-A1 | METHODS OF TREATING CANCER USING FUTIBATINIB, PEMBROLIZUMAB AND AT LEAST ONE ADDITIONAL CHEMOTHERAPEUTIC AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | WO | claimed |
| WO-2025046272-A1 | METHODS OF TREATING CANCER USING FUTIBATINIB AND PEMBROLIZUMAB | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | WO | claimed |
| EP-4507736-A1 | COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS | GILEAD SCIENCES, INC. (US) | 2025-02-19 | — | — | EP | claimed |
| US-20230181456-A1 | DRUG-LOADED BIODEGRADABLE MICROBEAD COMPOSITIONS INCLUDING DRUG-CONTAINING VESICULAR AGENTS | C.R. BARD, INC. | 2023-06-15 | — | — | US | claimed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | claimed |
| WO-2022232808-A1 | DOSING REGIMENS OF PEPTIDE CONJUGATES OF TOPOISOMERASE I INHIBITORS | Cybrexa 2, Inc. (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022228551-A1 | ADMINISTRATION SCHEME FOR THROMBOPOIETIN RECEPTOR AGONIST | 江苏恒瑞医药股份有限公司 | 2022-11-03 | — | — | WO | claimed |
| US-20220332839-A1 | USE OF PRG4 TO TREAT CANCER | LUBRIS LLC (US) | 2022-10-20 | — | — | US | claimed |
| EP-4000604-A1 | DRUG-LOADED MICROBEAD COMPOSITIONS, EMBOLIZATION COMPOSITIONS AND ASSOCIATED METHODS | C.R. Bard, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3997093-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114302950-A | Method for optimizing fermentation of euglena by utilizing engineering storage tank design | 诺贝尔根公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3976085-A1 | USE OF PRG4 TO TREAT CANCER | Lubris LLC (US) | 2022-04-06 | — | — | EP | claimed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558308-B2 | Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents | CHMP4B, CD44, LIPA | TOP1 280/4885MEN1 817/4885KMT2A 3178/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | TOP1 1789/4885MEN1 2116/4885KMT2A 414/4885 |
| US-20260034236-A1 | NEW DRUG COMPLEX | OPRM1, ABCC1, OPRD1 | TOP1 77/4885MEN1 1664/4885KMT2A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.